Evoke Pharma Posts 47 Percent Q2 Growth
Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, released its second quarter results on August 14, 2025. The most notable news from the earnings release was Net product sales increased 47% year-over-year to $3.8 million in Q2 2025, marking continued commercial momentum for its Gimoti nasal spray for diabetic gastroparesis. Net loss per share was $0.62 in Q2 2025. While GAAP revenue was $3.8 million, exceeding expectations by $0.004 million. Confidence in demand persisted as management affirmed its full-year net product sales outlook of approximately $16 million. Overall, the quarter showed solid sales growth but flagged persistent cost and profitability challenges as the company continues its push for broader adoption of its only commercial product.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Evoke Pharma is a U.S.-based pharmaceutical company specializing in treatments for gastrointestinal (GI) disorders. Its core focus is Gimoti, a nasal spray designed for adult patients with diabetic gastroparesis, a chronic disorder that impairs stomach emptying.
Source Fool.com
